Covid-19: Serum Institute, Bharat Biotech Vaccines Apply For Emergency Use In India; Covaxin To Be Launched In February
The head of the Serum Institute in India which is working on the development of the AstraZeneca based Covishield vaccine in the country has dropped an update about the emergency use approvals. Read on to know.
In the year 2020, the struggle to find a vaccine for Coronavirus is unstoppable. However, as per the latest updates, there’s a piece of good news with regards to the vaccine development. In India, the head of the Serum Institute which has tasked to develop the AstraZeneca based Covishield vaccine in the country now says, that the positive late state trial results of the candidates will allow it to seek emergency use approval by the year-end; before securing approval for a full introduction by February or March next year. India also expects a government bagged vaccine- Bharat Biotech’s Covaxin, to be launched as early as February.
Watch the video here:
Meanwhile, the late-stage trial of Russia’s SPUTNIK-V is also happening in the country. On Tuesday, the Union health ministry confirmed that the drug manufacturers Serum Institute of India and Bharat Biotech have applied for emergency use approval of their potential coronavirus vaccines, reported ANI. The development came a day after Serum Institute’s Chief Executive Officer Adar Poonawalla made the announcement on Twitter. More so, Union Health Ministry Secretary, Rajesh Bhushan, mentioned that as many as six vaccines were in the clinical stage trials in India and that some of the vaccines may soon get a licence. He added that some of the vaccine candidates may get licensed in the next few weeks.
Speaking about China, in the country, no supply deals have been struck with western drug-makers and instead, the government has partnered with private companies from within the country. China has approved 3 vaccines for emergency use for now. China has Sinovac vaccine to inoculate around 1 million people under an emergency use program. Meanwhile, Canada gets the first batch of Pfizer/BioNTech coronavirus vaccine. According to the Ministry of Health & Family Welfare, in India, while 75.58% of the new recovered cases are observed to be concentrated in 10 states/UTs; 75.82% of new COVID-19 cases are concentrated in 10 states & UTs. Whereas, 10 states/UTs account for 79.46% of 336 case fatalities as reported in the past 24 hours.
Visit the news section of ZEE5 app for more Entertainment, Trending News, Movies and Shows’ stories!